Semi-permeable membrane and a method of manufacturing the semi-permeable membrane thereof

Abstract

The invention discloses a biocompatible semi-permeable membrane. The semi-permeable membrane is manufactured by: providing an eggshell membrane; and immersing the eggshell membrane in an aqueous hydrogen peroxide solution with a concentration of 0.35 to 35% for 8 to 144 hours.

Claims

1. A method of manufacturing a semi-permeable membrane comprising: providing an eggshell membrane; immersing the eggshell membrane in an aqueous hydrogen peroxide solution with a hydrogen peroxide concentration of 0.35% to 35% for 8 to 144 hours; and removing the aqueous hydrogen peroxide from the eggshell membrane to obtain the semi-permeable membrane.

2. The method of manufacturing the semi-permeable membrane as claimed in claim 1, wherein the eggshell membrane is immersed in an aqueous hydrogen peroxide solution with a hydrogen peroxide concentration of 35% for 8 to 48 hours.

3. The method of manufacturing the semi-permeable membrane as claimed in claim 2, wherein the eggshell membrane is immersed in the aqueous hydrogen peroxide solution for 24 hours.

4. The method of manufacturing the semi-permeable membrane as claimed in claim 1, wherein the eggshell membrane is collected from a raw egg.

Description

BRIEF DESCRIPTION OF THE DRAWINGS

(1) The present invention will become more fully understood from the detailed description given hereinafter and the accompanying drawings which are given by way of illustration only, and thus are not limitative of the present invention, and wherein:

(2) FIG. 1 depicts FTIR spectra of the eggshell membrane (group A1) and the semi-permeable membrane of the invention (group A2).

(3) FIG. 2 depicts AFM images of the eggshell membrane (group B0, panel a) and the semi-permeable membrane of the invention (groups B1 to B5, panels b to f).

(4) FIG. 3 depicts optical images of the eggshell membrane (group B0, panel a) and the semi-permeable membrane of the invention (groups B6 to B10, panels b to f).

(5) FIG. 4 depicts optical images acquired after a blood droplet was placed on the eggshell membrane (group C1) and the semi-permeable membrane of the invention (group C2).

(6) In the various figures of the drawings, the same numerals designate the same or similar parts. Furthermore, when the term first, second, third, fourth, inner, outer, top, bottom and similar terms are used hereinafter, it should be understood that these terms refer only to the structure shown in the drawings as it would appear to a person viewing the drawings, and are utilized only to facilitate describing the invention.

DETAILED DESCRIPTION OF THE INVENTION

(7) The semi-permeable membrane of the invention is a modification of an eggshell membrane by immersing into an aqueous hydrogen peroxide solution (H.sub.2O.sub.2(aq)). Preferably, the semi-permeable membrane of the invention is manufactured as follows: providing the eggshell membrane, and immersing the eggshell membrane into the H.sub.2O.sub.2(aq) for 8 to 144 hours.

(8) In detail, the eggshell membrane is collected from a raw egg. Moreover, according to the purpose of the semi-permeable membrane, the eggshell membrane can be collected from the raw egg of different species. For example, in order to manufacture a thick semi-permeable membrane, the eggshell membrane can be collected from the raw egg of ostrich, Struthio camelus. In addition, the eggshell membrane derived from a hatchery byproduct is easily available and thus decreases the cost for manufacturing the semi-permeable membrane of the invention. Besides, the eggshell membrane generally consists of protein (approximately 90 wt %, which is the major ingredient of the eggshell membrane), lipids (3 wt %) and carbohydrates (2 wt %), and therefore poses no immunogenicity, high biocompatibility and decreased immune responses when applying to hemodialysis.

(9) In a preferable embodiment, the eggshell membrane, collected from the raw egg, is obtained as follows: Breaking the shell of the raw egg in the non-air cell end, the smaller one of the shell; flow outing the yolk and the albumen from the non-air cell end; forming a hole at the air cell end, the larger one of the shell; pouring water into the air cell; and separating the shell and the eggshell membrane.

(10) The eggshell membrane is further immersed in the H.sub.2O.sub.2(aq), forming cystine by cysteine oxidation to obtain the semi-permeable membrane of the invention. The H.sub.2O.sub.2(aq) can be chose as a commercially available H.sub.2O.sub.2(aq) with a concentration of 35% or as a diluent of the commercially available H.sub.2O.sub.2(aq) with water. Preferably, the H.sub.2O.sub.2(aq) has a concentration between 0.35% and 35%, and more particularly, the H.sub.2O.sub.2(aq) has a concentration of 35%. Moreover, immersing time is selected to be 8 to 144 hours, but is still adjustable according to the concentration of the H.sub.2O.sub.2(aq). For example, when using the 35% H.sub.2O.sub.2(aq), the immersing time can preferably be 8 to 48 hours, and in particular be 24 hours.

(11) To prove the semi-permeable membrane of the invention comprises cystine formed by cysteine oxidation and a shrunken pore size, chemical changes are demonstrated by FTIR and the pore size is observed by AFM topography image.

(12) Trial (A). Chemical Changes of the Semi-Permeable Membrane of the Invention

(13) Referring to Table 1, FTIR (Fourier transform infrared spectroscopy) is performed on the eggshell membrane (group A1) and the semi-permeable membrane of the invention (group A2).

(14) TABLE-US-00001 TABLE 1 H.sub.2O.sub.2 immersion Groups Concentration Time A1 A2 35% 24 hours

(15) Referring to FIG. 1, group A1 contains peaks at 3274 cm.sup.1 (OH and NH stretching), 2929 cm.sup.1 (CH stretching), 1643 cm.sup.1 (amide CO stretching), 1536 cm.sup.1 (amide NH bending), 1451 cm.sup.1 (CH.sub.2 scissoring), 1109 cm.sup.1 (amine CN stretching), and 661 cm.sup.1 of (CS stretching). However, in group A2, new peaks appears at 1039 cm.sup.1 and 609 cm.sup.1 due to the formation of a SS bond, which shifted the a v(CS) stretching vibration at 661 cm.sup.1 down to 609 cm.sup.1, and the CN stretching at 1109 cm.sup.1 down to 1039 cm.sup.1. That is, the H.sub.2O.sub.2 immersion oxidizes cysteine, triggers the formation of the SS bond, forming cystine, and finally results in the rearrangement of the fibrils and reduction in pore size.

(16) Trial (B). Pore Sizes of the Semi-Permeable Membrane of the Invention

(17) Referring to Table 2, the eggshell membrane (group B0) is used as a negative control. The semi-permeable membrane of the invention manufactured by immersing the eggshell membrane for different time is used as groups B1 to B5. Surface topographies of the groups B0 to B5 are analyzed by AFM (atomic force microscope).

(18) TABLE-US-00002 TABLE 2 H.sub.2O.sub.2 immersion Groups Concentration Time FIG. 2 B0 panel(a) B1 35% 4 hours panel(b) B2 35% 8 hours panel(c) B3 35% 12 hours panel(d) B4 35% 20 hours panel(e) B5 35% 24 hours panel(f)

(19) Referring to FIG. 2, all of the groups B0 to B5 show a cross-linked 3-D fiber-mesh structure. The width of the fibres is 2.50.5 m. Moreover, before H.sub.2O.sub.2 immersion, the fibres of the eggshell membrane exhibit visible pores with pore sizes of 3 to 10 m (group B0, as shown in panel (a)). The semi-permeable membrane of the invention has a relatively smaller pore size (group B1 to B5, as shown in panels (b) to (f)). In addition, pore size shrinks with the increase of the immersion time. For example, the pore size of group B5 is approximately between 1 and 5 m.

(20) Furthermore, to prove the diluent of the commercially available H.sub.2O.sub.2(aq) with water can be used to manufacture the semi-permeable membrane of the invention, different concentration of the H.sub.2O.sub.2(aq) are used. The different concentration of the H.sub.2O.sub.2(aq) and the immersion time are listed in TABLE 3.

(21) TABLE-US-00003 TABLE 3 H.sub.2O.sub.2 immersion Groups Concentration Time FIG. 3 B0 panel(a) B6 7% 48 hours panel(b) B7 3.5% 72 hours panel(c) B8 1.75% 72 hours panel(d) B9 0.7% 132 hours panel(e) B10 0.35% 144 hours panel(f)

(22) Referring to FIG. 3, the diluent with concentration higher than 0.35% also can be used to manufacture the semi-permeable membrane of the invention. Moreover, as the concentration decreases, the immersion time should increase to manufacture the semi-permeable membrane with the similar pore size.

(23) Trial (C). Blood Osmosis Test of the Semi-Permeable Membrane of the Invention

(24) To prove the semi-permeable membrane can be used for homodialysis, the following trial (C) is performed.

(25) Blood is collected from a 3 week-old male Sprague-Dawley rat. A 10 L sample of the rat's blood is placed into a micro tube and diluted with 90 L of 0.85 NaCl.sub.(aq) to prepare a blood sample stock solution. 1.5 L of the blood sample stock solution is placed on the eggshell membrane (group C1) and the semi-permeable membrane of the invention (group C2), respectively. The droplet penetration is observed by using an optical microscope.

(26) TABLE-US-00004 TABLE 3 H.sub.2O.sub.2 immersion Groups Concentration Time C1 C2 35% 24 hours

(27) Referring to FIG. 4, a complete penetration of the blood droplet on the eggshell membrane (group C1, as shown in panel (a)) because of the larger pore size of the eggshell membrane. In contrast, by H.sub.2O.sub.2 immersion, the semi-permeable membrane of the invention has a relative smaller pore size, and therefore the red blood cells, the round particles shown in panel (b), cannot penetrate the semi-permeable membrane of the invention.

(28) In conclusion, the semi-permeable membrane of the invention is manufactured by immersing the eggshell membrane into the aqueous hydrogen peroxide solution. The eggshell membrane poses no immunogenicity and high biocompatibility, and therefore shows decreased immune responses when applying to hemodialysis.

(29) Moreover, not only by using the easily available and cheap eggshell, but also by the easy process, the method of manufacturing the semi-permeable membrane of the invention can be a low cost method to manufacture the semi-permeable membrane.

(30) Furthermore, by immersing the eggshell membrane into the aqueous hydrogen peroxide solution, cystine is formed by cysteine oxidation and further shrinks the pores of the semi-permeable membrane. That is to say, the method of manufacturing the semi-permeable membrane of the invention can be used to adjust the pore size of the final product, the semi-permeable membrane, thereby being suitable to filtrate or dialyze substances with different particle sizes.

(31) Although the invention has been described in detail with reference to its presently preferable embodiment, it will be understood by one of ordinary skill in the art that various modifications can be made without departing from the spirit and the scope of the invention, as set forth in the appended claims.